10 IPOs entered the public market this past week headlined by Airbnb (ABNB) and DoorDash (DASH), which completed the largest and second-largest IPOs of 2020, respectively. They were joined by 20 blank check IPOs in the...read more
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised $193 million by offering 8.4 million shares at $23, the high end of the upwardly revised range of $22 to $23. The company offered 1.4 million more...read more
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised the proposed deal size for its upcoming IPO on Thursday.
The Emeryville, CA-based company now plans to raise $158 million by offering 7 million...read more
4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, announced terms for its IPO on Monday. The Emeryville, CA-based company plans to raise $100 million by offering 4.8 million shares at a price range of $20 to $22....read more
US IPO Weekly Recap: Airbnb and DoorDash make their public debuts in a 10 IPO week
10 IPOs entered the public market this past week headlined by Airbnb (ABNB) and DoorDash (DASH), which completed the largest and second-largest IPOs of 2020, respectively. They were joined by 20 blank check IPOs in the...read more
Gene therapy biotech 4D Molecular Therapeutics prices further upsized IPO at $23, the high end of the upwardly revised range
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised $193 million by offering 8.4 million shares at $23, the high end of the upwardly revised range of $22 to $23. The company offered 1.4 million more...read more
Gene therapy developer 4D Molecular Therapeutics increases deal size by 58% ahead of $158 million IPO
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Emeryville, CA-based company now plans to raise $158 million by offering 7 million...read more
Gene therapy developer 4D Molecular Therapeutics sets terms for $100 million IPO
4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, announced terms for its IPO on Monday. The Emeryville, CA-based company plans to raise $100 million by offering 4.8 million shares at a price range of $20 to $22....read more